Gelteq shares surge 14.71% after-hours on positive preclinical data showing 38–45% bioavailability boost.

Gelteq (NASDAQ: GELS) surged 14.71% in after-hours trading following the release of positive preclinical data demonstrating its proprietary gel-based drug delivery platform enhanced bioavailability by 38–45% for a water-soluble antihistamine. The results, published November 24, 2025, showed significantly higher systemic exposure (AUC) and peak concentration (Cmax) while maintaining comparable time-to-peak (Tmax), validating the platform’s ability to improve drug absorption without delaying onset. CEO Nathan Givoni emphasized the findings’ commercial potential, noting the technology’s applicability across broader water-soluble drug classes and its role in advancing FDA approval pathways and partnership opportunities. The data reinforced investor confidence in Gelteq’s platform as a transformative solution for pharmaceutical and nutraceutical delivery, directly aligning with the stock’s sharp after-hours increase.